Laura Ferreira Provenzano, MD
Nephrology · Cleveland, OHNPI 1003075276
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,876 of the $2,602 with a category attached, or 72.1%. 6 manufacturers reported payments, led by Travere Therapeutics, Inc. at 36.2% of the total. 2025 is the largest year on record at $966, 3.1 times the $315 reported in 2019.
Across 32 payments — averaging $81.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$942
- Aurinia Pharma U.S., Inc.$605
- Otsuka America Pharmaceutical, Inc.$463
- GSK$380
- Nxstage Medical, Inc.$170
- Otsuka Pharmaceutical Development & Commercialization, Inc.$42
Across 7 payments — averaging $6863.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$30K
- Aurinia Pharma U.S., Inc.$18K
What the payments were for
- Travel & lodging$56922%
- Food & beverage$1,87672%
- Education$1566%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 9 | $942 |
| Aurinia Pharma U.S., Inc. | 7 | $605 |
| Otsuka America Pharmaceutical, Inc. | 8 | $463 |
| GSK | 4 | $380 |
| Nxstage Medical, Inc. | 2 | $170 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,602 in reported general payments places this provider in the 70th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 14 | $41,214 |
| FarxigaDapagliflozin Propanediol | 19 | $25,531 |
| JardianceEmpagliflozin | 11 | $14,802 |
| Mycophenolate Mofetil | 18 | $4,861 |
| Nifedipine ErNifedipine | 27 | $2,346 |
| Sevelamer Carbonate | 15 | $2,246 |
| Torsemide | 67 | $1,600 |
| Amlodipine Besylate | 80 | $646 |
| Gentamicin Sulfate | 15 | $602 |
| Carvedilol | 64 | $593 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $571 |
| Losartan Potassium | 63 | $508 |
| Calcium Acetate | 11 | $451 |
| Hydralazine Hcl | 23 | $356 |
| Potassium Chloride | 16 | $286 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cleveland
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Sevag DemirjianCleveland$158K
- Elias BassilCleveland$80K
- Ali MehdiCleveland$76K
- Amitkumar PatelCleveland$70K
- Emilio PoggioCleveland$41K
- Corey CavanaughCleveland$35K
- James SimonCleveland$29K
- Ziad ZakyCleveland$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.